newsfilter
← Latest News
Business Wire·

ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 2018 American Society of Hematology (ASH) Annual Meeting

BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq:ARQL) today announced that it will present clinical data on the company’s BTK inhibitor, ARQ 531, in a poster presentation at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition to be held from December 1 to 4, 2018 in San Diego.